Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs GLENMARK PHARMA - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES GLENMARK PHARMA DIVIS LABORATORIES/
GLENMARK PHARMA
 
P/E (TTM) x 66.0 -31.4 - View Chart
P/BV x 7.1 2.9 250.1% View Chart
Dividend Yield % 0.9 0.3 334.3%  

Financials

 DIVIS LABORATORIES   GLENMARK PHARMA
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-23
GLENMARK PHARMA
Mar-23
DIVIS LABORATORIES/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs4,641487 952.7%   
Low Rs2,730349 782.5%   
Sales per share (Unadj.) Rs292.6460.4 63.6%  
Earnings per share (Unadj.) Rs68.713.4 513.5%  
Cash flow per share (Unadj.) Rs81.635.0 232.9%  
Dividends per share (Unadj.) Rs30.002.50 1,200.0%  
Avg Dividend yield %0.80.6 136.1%  
Book value per share (Unadj.) Rs480.9335.1 143.5%  
Shares outstanding (eoy) m265.47282.17 94.1%   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x12.60.9 1,387.2%   
Avg P/E ratio x53.731.3 171.7%  
P/CF ratio (eoy) x45.211.9 378.5%  
Price / Book Value ratio x7.71.2 614.4%  
Dividend payout %43.718.7 233.7%   
Avg Mkt Cap Rs m978,378117,953 829.5%   
No. of employees `000NANA-   
Total wages/salary Rs m9,75027,810 35.1%   
Avg. sales/employee Rs Th00-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th00-  
INCOME DATA
Net Sales Rs m77,675129,901 59.8%  
Other income Rs m3,4473,168 108.8%   
Total revenues Rs m81,122133,069 61.0%   
Gross profit Rs m23,69115,125 156.6%  
Depreciation Rs m3,4326,113 56.1%   
Interest Rs m203,496 0.6%   
Profit before tax Rs m23,6868,685 272.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,4534,911 111.0%   
Profit after tax Rs m18,2343,774 483.1%  
Gross profit margin %30.511.6 261.9%  
Effective tax rate %23.056.5 40.7%   
Net profit margin %23.52.9 808.0%  
BALANCE SHEET DATA
Current assets Rs m97,43798,737 98.7%   
Current liabilities Rs m15,33150,455 30.4%   
Net working cap to sales %105.737.2 284.4%  
Current ratio x6.42.0 324.8%  
Inventory Days Days87 125.1%  
Debtors Days Days842115 731.4%  
Net fixed assets Rs m51,12876,920 66.5%   
Share capital Rs m531282 188.1%   
"Free" reserves Rs m127,14094,281 134.9%   
Net worth Rs m127,67194,563 135.0%   
Long term debt Rs m038,521 0.0%   
Total assets Rs m148,565175,658 84.6%  
Interest coverage x1,209.53.5 34,712.9%   
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x0.50.7 70.7%   
Return on assets %12.34.1 296.9%  
Return on equity %14.34.0 357.9%  
Return on capital %18.69.2 202.9%  
Exports to sales %85.70-   
Imports to sales %19.80-   
Exports (fob) Rs m66,537NA-   
Imports (cif) Rs m15,378NA-   
Fx inflow Rs m66,53746,464 143.2%   
Fx outflow Rs m15,71512,712 123.6%   
Net fx Rs m50,82233,751 150.6%   
CASH FLOW
From Operations Rs m24,5976,254 393.3%  
From Investments Rs m-27,076-5,285 512.3%  
From Financial Activity Rs m-7,972-775 1,029.2%  
Net Cashflow Rs m-10,451325 -3,215.6%  

Share Holding

Indian Promoters % 51.9 46.7 111.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 36.7 34.7 106.0%  
FIIs % 14.9 23.7 62.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 48.1 53.4 90.1%  
Shareholders   354,482 209,931 168.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   SUN PHARMA    CIPLA    DR. REDDYS LAB    ZYDUS LIFESCIENCES    MANKIND PHARMA    


More on Divis Laboratories vs Glenmark Pharma

No comparison is complete without understanding how the stock prices have performed over a period of time.

Here's a brief comparison:

Divis Laboratories vs Glenmark Pharma Share Price Performance

Period Divis Laboratories Glenmark Pharma S&P BSE HEALTHCARE
1-Day 2.14% -0.57% 1.18%
1-Month -2.15% 5.16% -0.75%
1-Year 22.51% 112.94% 61.82%
3-Year CAGR -1.38% 27.51% 18.16%
5-Year CAGR 15.77% 8.05% 19.79%

* Compound Annual Growth Rate

Here are more details on the Divis Laboratories share price and the Glenmark Pharma share price.

Moving on to shareholding structures...

The promoters of Divis Laboratories hold a 51.9% stake in the company. In case of Glenmark Pharma the stake stands at 46.7%.

To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of Divis Laboratories and the shareholding pattern of Glenmark Pharma.

Finally, a word on dividends...

In the most recent financial year, Divis Laboratories paid a dividend of Rs 30.0 per share. This amounted to a Dividend Payout ratio of 43.7%.

Glenmark Pharma paid Rs 2.5, and its dividend payout ratio stood at 18.7%.

You may visit here to review the dividend history of Divis Laboratories, and the dividend history of Glenmark Pharma.

For a sector overview, read our pharmaceuticals sector report.



Today's Market

Sensex Today Rallies 639 Points | Suzlon Energy Surges 5%, Grasim Industries 4% | 3 Reasons Why Indian Share Market is Rising Sensex Today Rallies 639 Points | Suzlon Energy Surges 5%, Grasim Industries 4% | 3 Reasons Why Indian Share Market is Rising(Closing)

After opening the day on positive note, Indian share markets gained the momentum as the session progressed and ended on firm footing.